Travere Therapeutics Inc (NASDAQ:TVTX) currently has a daily average trading volume of 1.78M but it saw 2273098 shares traded in last market. With a market cap of 1.20B USD, the company’s current market price of $13.49 came falling about -5.99 while comparing to the previous closing price of $14.35. In past 52 weeks, the stock remained buoying in the range of price level as high as $25.29 and as low as $5.12. In the recent trading on the day, stock has struck highest price mark of $13.175 while lowest mark touched by it was $14.555.
Taking a look at 20-day trading activity of Travere Therapeutics Inc (TVTX) gives us an average price of $18.38, while its current price level is -46.66% below from 52-week high level whereas it is 163.48% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $19.94 while that of 200 days or SMA-200 reads an average of $15.87. A closer look into the stock’s movement over the week reveals that its volatility is standing at 12.78% during that period while stretching the period over a month that decreases to 7.20%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 25.54 which implies that the stock is in oversold territory.
Wells Fargo upgraded its recommendation for the stock as a “Overweight” from “Equal Weight” on October 21, 2024 while assigning a price target range of $9-$27.
Over the week, TVTX’s stock price is moving -18.54% down while it is -29.99% when we observe its performance for the past one month. Year-to-date it is -22.56% down and over the past year, the stock is showing an upside performance of 96.65%.
Currently, Travere Therapeutics Inc’s total number of outstanding shares is 87.45M with 0.70% of that held by the insiders while 109.20% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -83.18% and return on equity (ROE) at -246.75%. It has a 12.54 of forward P/E ratio. Stock’s beta reads 0.96. Stock has a price to book (P/B) ratio of 19.97 while price to sale or P/S ratio amounts to 5.14. Its return on asset (ROA) is -46.37% on average.
